Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications

• Late divergence of survival curves of treated patients and controls is commonly seen in successful cancer immunotherapy trials. Although late survival curve divergence may be caused by a delayed action of therapy, it may also be related to early effects of the treatment. We suggest that late survival divergence most often reflects a specific benefit of therapy for patients who suffer from a comparatively slow progression of disease. The occurrence of delayed survival curve divergence has important implications for the statistical analysis of immunotherapy trials. Thus, it leads to non-proportional hazard ratios that make commonly used statistical tests, e.g., the logrank test, suboptimal. It is therefore suggested that the statistical analysis of immunotherapy trials primarily should be based on a test that compares the survival curves at or after a prespecified, fixed, late time point.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Immunotherapy

Survival analysis

Kaplan-Meier

Treatment outcome

Late divergence

Statistical

RESISTANT PROSTATE-CANCER

RANDOMIZED PHASE-III

METASTATIC MELANOMA

CUTANEOUS MELANOMA

LOGRANK TEST

END-POINTS

FOLLOW-UP

VACCINE

VITESPEN

BLOCKADE

Late

divergence

Statistical models

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)